

AMOÉBA: A NEW LEGAL STRUCTURE TO MAXIMISE COMMERCIAL ACTIVITIES

Subsidiarisation of biocontrol and cosmetics sales activities

Chassieu (France), July 2, 2024 – 8:30am - Amoéba (FR0011051598 - ALMIB), an industrial greentech specialising in the treatment of microbiological risk, announces a major legal reorganisation designed to strengthen the development of its commercial activities in the biocontrol and cosmetics sectors, and to create value for its shareholders.

Following confirmation of the potential of cosmetics in its future development (see [Press Release of June 10, 2024](#)), Amoéba is now committed to expanding two distinct commercial activities: biocontrol and cosmetics.

Amoéba's Board of Directors has approved the creation of a new legal structure, with the aim of improving visibility in each of these markets, providing a dedicated sales force and setting up a long-term organisation tailored to the specific challenges. This reorganisation will include :

- **The listed operating parent company**, based in Chassieu (Amoéba). This existing entity will bring together all R&D and production activities, thereby driving Amoéba's technological platform. It will hold the patents and provide support activities.
- **Two commercial operating companies specialised by market**, owned by the parent company: one dedicated to biocontrol activities and the other to cosmetics.

This new organisation will be implemented in the second half of 2024.

"The purpose of this strategic change is to develop industrial, commercial and financial partnerships directly at subsidiary level. By optimising our resources and adapting our structures to the specific features of each market, we are creating the conditions for sustainable growth for the Amoéba Group and its shareholders" explained Jean-François Doucet, Chief Executive Officer of Amoéba.

About Amoéba:

Founded in 2010, Amoéba is a greentech based in Chassieu (Lyon, France) with the ambition to become a major player for the treatment of microbiological risk in the water, crop protection and cosmetic sectors.


Based on the natural properties of a unique, exclusively patented, microorganism, the only one of its kind in the world, our biological solutions offer a viable alternative to the chemical products that are widely used in the industry today. Amoéba is currently focused on the global biocontrol market for plant protection and the cosmetics market. As the market release of phytosanitary products is subject to local regulatory approvals, the Company has completed the regulatory processes required and in 2022 obtained approval for its active substance in the United States and its recommendation for approval in Europe, issued by the Austrian authority. As the cosmetic application does not require prior approval from a relevant authority in Europe and the United States, the party responsible for bringing the formulated cosmetic product to market must carry out a self-assessment of its safety.

Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. For more information, please visit www.amoeba-nature.com.

Contacts:

Amoéba

Jean-François Doucet
Chief Executive Officer


 +33 (0)4 26 69 16 00

 jf.doucet@amoeba-nature.com

Calyptus

Investor & Press Relations

Nicolas Hélin / Mathieu Calleux

 +33 (0)1 53 65 37 90 / 91

 amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning Amoéba which are based on its own assumptions and estimates and on information that is currently available to us. However, Amoéba gives no assurance that the estimates contained in such forward-looking statements will be verified, with these estimates subject to numerous risks, including the risks set forth in Amoéba's universal registration document filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 29, 2024 under number D24-0352 and available on the Amoéba website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to Amoéba or not currently considered material by Amoéba. The occurrence of all or part of such risks could cause Amoéba's actual results, financial conditions, performance, or achievements to be materially different from such forward-looking statements.